The average cost per month for a branded oncology drug treatment in the U.S. is about $10,000, around double where it was a decade ago, according to a new report by IMS Institute for Healthcare Informatics. Read More
With first quarter earnings season in full swing investors have not been overly impressed with what biotech companies are reporting. As a result, the overall sector’s performance on the capital markets has dipped so far this month. There have been a number of stocks that beat earnings estimates but were still hit by selling. Read More
There has been a great deal of discussion lately about productivity. Namely, the overarching theme is on how to bring new medicines to patients faster and at less cost. It’s no secret that R&D productivity has been challenged over the past few years despite the availability and implementation of technology designed to screen for promising molecules. Read More
